http://www.youtube.com/watch?v=0mYBSayCsH0
Printable View
I made it clear I don't have any so have no reason to be nervous. Negative? In the short term I'm not as positive sales will be as stellar as many posters here think. I have nothing to gain or lose financially by offering this opinion.
XRO currently has paying customers.
Hancocks - what is the cost of those tests compared to CxB which I think from reading above is about $1k (??) and is done monthly (??).
Disc: Not a holder as haven't researched enough but PEB does seem to be one of the interesting stocks for 2013.
I agree with SPC.
Just a question to those who are wiser than me. Is it possible for a takeover? I dont know what term would be, but big companies such as Merck will frequently buy out companies/IP like this to have their product, is this possible in PEBs case?
I know for a fact that companies like MSD have whole divisions responsible for researching companies like PEB.
Do not underestimate the ability of the American Medical system to do absolutely stupid things for purely political reasons-There are plenty of inferior tests being used as we speak,for reasons that dont put patients first.
No im simply saying its not a given.
The politics in America are mind boggling. There are lobbyists in the medical community that wield huge influence on what actually happens.
All it takes is someone connected to the inferior product ,who is also in a position of power,especially in terms of the large insurance contracts to keep a better product from getting a foothold.
America is rife with conflict of interest situations--a bit like the past vice president [Chaney]being on the board of Halliburton[builds military bases] while being involved with making decisions on going to war.
The military and Pharmaceutical-medical, are the 2 big ones.
Im not saying this is definitely the case ,but in light of the speculative nature of whats been happening in the last 3 weeks with the share price,its one more thing to put into the mix when determining your appetite for risk.